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Abstract
Background: The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) plays a key role in the B-cell growth
transformation by initiating and maintaining the proliferation of infected B-cell upon EBV infection in vitro. Most
studies about EBNA-2 have focused on its functions yet little is known for its intertypic polymorphisms.
Results: Coding region for amino acid (aa) 148-487 of the EBNA-2 gene was sequenced in 25 EBV-associated
gastric carcinomas (EBVaGCs), 56 nasopharyngeal carcinomas (NPCs) and 32 throat washings (TWs) from healthy
donors in Northern China. Three variations (g48991t, c48998a, t49613a) were detected in all of the samples (113/
113, 100%). EBNA-2 could be classified into four distinct subtypes: E2-A, E2-B, E2-C and E2-D based on the deletion
status of three aa (294Q, 357K and 358G). Subtypes E2-A and E2-C were detected in 56/113 (49.6%), 38/113 (33.6%)
samples, respectively. E2-A was observed more in EBVaGCs samples and subtype E2-D was only detected in the
NPC samples. Variation analysis in EBNA-2 functional domains: the TAD residue (I438L) and the NLS residues
(E476G, P484H and I486T) were only detected in NPC samples which located in the carboxyl terminus of EBNA-2
gene.
Conclusions: The subtypes E2-A and E2-C were the dominant genotypes of the EBNA-2 gene in Northern China.
The subtype E2-D may be associated with the tumorigenesis of NPC. The NPC isolates were prone harbor to more
mutations than the other two groups in the functional domains.
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Background
Epstein-Barr virus (EBV) is a ubiquitous herpes virus
infecting the majority of human populations. Its genome
approximately has 172,000 base pairs [1]. EBV plays an
important role in various human tumors, such as Bur-
kitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC)
[2-4] and causes the benign lymphoproliferative disease
infectious mononucleosis [5]. It is also associated with
10% of gastric carcinomas (GC) [6,7], often called EBV-
associated gastric carcinoma (EBVaGC). In Northern
China this rate is about 7.0% according to our previous
study [8].
In vitro, EBV can latently infect and immortalize
human B lymphocytes. EBNA-LP and EBNA-2 are firstly
expressed viral genes, followed by the other latency
genes EBNA-1, EBNA-3A, EBNA-3B, EBNA-3C, latent
membrane protein (LMP) -1, LMP-2 and the small non-
polyadenylated RNAs (EBERs) [9-12]. The role of
EBNA-2 in B-cell growth transformation is closely
linked to transactivation of cellular and viral gene
expression. The expression of the LMP genes and B-cell
genes, including CD23, CD21 and c-fgr are transacti-
vated by EBNA-2 [13]. By activating viral as well as cel-
lular target genes, EBNA-2 initiates the transcription of
a cascade of primary and secondary target genes, which
eventually govern the activation of the resting B-cell,
cell cycle entry and proliferation of the growth trans-
formed cells. * Correspondence: qdluobing@yahoo.com
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known as type 1 and 2) according to the sequence of
the EBNA-2 gene. EBV-A shows more efficient trans-
forming activity in vitro than EBV-B type, and is predo-
minantly found in EBV-associated diseases [14]. The
amino acid sequences of EBNA-2 in EBV type A and B
are remarkably divergent. This divergence is potentially
useful for predicting essential domains of the protein.
The protein consists of a lightly negatively charged,
well-conserved amino terminus (aa 1 to 58); a polypro-
line domain which differs in length (aa 59 to 95); a
short conserved charged domain (aa 96 to 134); a long
divergent domain (aa 135 to 281); a moderately well
conserved proline-rich domain (aa 282 to 330); a mod-
erately well conserved basic domain, including an argi-
nine-glycine repeat motif (aa 331 to 369); a moderately
well conserved acidic domain (aa 370 to 475); and a
short, basic, conserved carboxyl terminus (aa 476 to
487) [15]. As a transcription factor, EBNA-2 contains
three domains critical for its transcription regulation
function, the self-association domain (aa 101-214),
transactivation domain (TAD) (aa 424-468), and nuclear
localization signals (NLS) (aa 284-341 and aa 468-487)
[4,16,17]. We hypothesized that sequence variations in
this region more likely affect its regulation function and
therefore are possibly related to the development of
malignancy.
Most studies on sequence variations of the EBV gen-
ome have focused on the populations in Southern
China, the endemic area of NPC [18-22]. However, the
nucleotide sequence of EBV type A and B is different
extensively and consistently in EBNA-2, -3A, -3B and
-3C genes [23]. No report has been available for interty-
pic polymorphisms of EBNA-2 gene in EBV-positive
NPCs and EBVaGCs samples in China. This study ana-
lyzed the key nucleotide sequences of EBNA-2 gene that
codes aa from 148 to 487 and determined the variations
of this gene in EBVaGCs, NPCs and TWs in Northern
China, a non-NPC endemic region.
Results
Sequence variation of EBNA-2 gene
The sequences of EBNA-2 gene for aa 148-487 were
determined in 25 EBVaGCs, 56 NPCs and 32 TWs sam-
ples by PCR sequencing. All the sequences were com-
pared with the prototype B95-8 sequence. Nucleotide
changes were detected in 20 loci, 10 of which resulted
in aa changes (Figure 1). Among the 20 loci with
nucleotide changes, three nucleotide mutations
(g48991t, c48998a and t49613a) were detected in all the
EBVaGC, NPC and TW samples (113/113, 100%) (Fig-
ure 1). According to whether there was a deletion in the
sequences, 4 distinct subtypes of EBNA-2 were classi-
fied, namely subtype E2-A (no aa deletion), E2-B (aa
294Q deletion), E2-C (aa 357K, 358G deletion), and E2-
D (aa 294Q, aa 357K and 358G deletion). Two subtypes,
E2-A and E2-C, were found to be dominant in the total
specimens. The E2-D pattern was only detected in the
NPC samples (Table 1).
Fifty-six of 113 samples (49.6%) were detected in sub-
type E2-A (Table 1). This type had six non-silent muta-
tions (P291T, R413G, I438L, E476G, P484H and I486T)
and four silent mutations (383cct-cca, 408gcc-gca,
417acg-aca and 470tca-tct) in addition to the three com-
mon mutations (Figure 1). Interestingly, the four silent
mutations and five non-silent mutations (R413G, I438L,
E476G, P484H and I486T) in this subtype were only
detected in 12 NPC samples. All these mutations are
located in the EBNA-2 acidic domain.
The second common subtype E2-C was detected in
33.6% (38/113) of the tested samples, which contained
two aa (357K, 358G) deletions (Table 1). Residue P291T
were present in 6 NPC samples and the residue R413G
was detected only in TW392.
The subtype E2-B was detected in 8 samples with the
common deletion of aa 294Q. Interestingly, subtype E2-
D (aa 294Q, 357K, 358G deletion) was only detected in
the NPC samples. The residue P291T mutation existed
in 6 NPC samples (Figure 1).
Distribution of EBNA2 gene subtypes in EBVaGCs, NPCs,
and TWs
The frequency of EBNA-2 subtypes in EBVaGCs, NPCs
and TWs of healthy donors was summarized in Table 1.
Fisher’s exact test was used to determine the difference
of the EBNA2 subtypes among the EBVaGCs, NPCs and
the TWs. E2-A and E2-C were dominant subtypes in
the tested specimens. E2-A was detected in 49.6% (56/
113) of total specimens, 18/25(72%) in EBVaGCs, 22/56
(39.3%) in NPCs, and 16/32 (50%) in TWs. E2-C was
found in 33.6% (38/113) specimens, including 5/25
(20%) EBVaGCs, 20/56(35.7%) NPCs, and 13/32 (40.6%)
TWs (Table 1). The proportion of the E2-A in
EBVaGCs (72%, 18/25) was significantly higher than in
NPC (39.3%, 22/56) or TWs (50%, 16/32). The E2-D
subtype was only detected in the NPC samples (Table 1)
(P = 0.008).
Variation analysis in EBNA-2 functional domains
EBNA-2 carries the characteristic features common to
all transcription factors: TAD, NLS and a region which
mediates promoter contact (Figure 2 and 3). The aa
mutations in EBNA-2 functional domains are summar-
ized in Table 2. The mutation at residue R163M was
detected in all samples in the self-association domain.
Interestingly, the mutations in TAD residue (I438L) and
the NLS residues (E476G, P484H and I486T) were only
detected in NPC samples which located in the carboxyl
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Figure 1 Aa 148-487 of the EBNA-2 gene sequence variations in EBVaGC, NPC biopsies and TWs of healthy donors in Northern China.
The aa (148-487) and their corresponding nucleotide sequence variations of the EBNA-2 in the EBVaGC, NPC and TW from healthy donors in
Northern China. Numbers on the top correspond to the aa and nucleotide positions of the gene under which the B95-8 prototype aa and
nucleotide sequences are listed. Different subtypes are noted on the left of the table, while the specimens showing identical sequences to each
other are represented by a sample in that group listed in the second column (such as GC85, T257...). The number in the parenthesis separated
by “/” denotes the number of sample isolates with the identical sequence from EBVaGC, NPC and TW, respectively. ‘*’ stands for the deletion of
an aa. The previously reported mutations at positions 49102 and 49136 were not detected in isolates from our area. A 51bp deletion was at
nucleotide 49102 and a triplet insertion of ctc was at nucleotide 49136 [29].
Table 1 Distribution of EBNA-2 gene subtypes (aa 148-487) in the EBVaGC, NPC and TWs
Subtype EBVaGC (n = 25) NPC
(n = 56)
TWs
(n = 32)
Total
(n = 113)
E2-A 18 (72%) 22 (39.3%) 16 (50%) 56 (49.6%)
E2-B 2 (8%) 3 (5.4%) 3 (9.4%) 8 (7.1%)
E2-C 5 (20%) 20 (35.7%) 13 (40.6%) 38 (33.6%)
E2-D 0 11 (19.6%) 0 11 (9.7%)
EBVaGCs, EBV-associated gastric carcinomas; NPC, nasopharyngeal carcinomas; TWs, throat washings from healthy donors.
Wang et al. Virology Journal 2012, 9:49
http://www.virologyj.com/content/9/1/49
Page 3 of 81 4 8                163  165            
RGLILPQGPQTAPQARLVQPHVPPLRPTAPTILSPLSQPRLTPPQPLMMPPRPTP 
                            S e l f - a s s o c i a t i o n   ( 1 4 8 - 2 1 4 )  
                   M   ( 2 5 / 5 6 / 3 2 )   
                
PTPLPPATLTVPPRPTRPTTLPPTPLLTVLQRPTELQPTPSPPRMHLPVLHVPDQ 
 
 
                                         291  294    CR5  (296-309) 
SMHPLTHQSTPNDPDSPEPRSPTVFYNIPPMPLPPSQLPPPAAPAQPPPGVINDQ
                                                 
                                   ( 1 / 1 4 / 3 )   T   D e l   ( 2 / 1 4 / 3 )  
        CR6  (320-327)         RG  (331-369)                357  358 
QLHHLPSGPPWWPPICDPPQPSKTQGQSRGQSRGRGRGRGRGRGKGKSRDK 
         NLS (284-341)                                                
                                                          Del (5/31/13) 
        370             383                              408   413 
QRKPGGPWRPEPNTSSPSMPELSPVLGLHQGQGAGDSPTPGPSNAAPVCRNS 
                                                               
                                                        ( 1 1 / 6 / 1 0 )   G  
417                       438                                     470
HTATPNVSPIHEPESHNSPEAPILFPDDWYPPSIDPADLDESWDYIFETTESPSS 
                               T A D   ( 4 2 4 - 4 6 8 )               
                           L   ( 0 / 3 / 0 )  
       476      484  486  487 
DEDYVEGPSKRPRPSIQ 
      NLS (468-487)             
                
G  (0/14/0)      T  (0/14/0) 
H (0/4/0)  
Figure 2 Amino acid sequence of the aa 148-487 in EBNA-2 gene and the mutated amino acids in isolates from EBVaGCs, NPCs and
TWs in Northern China. Schematic illustration of the aa 148-487 of EBNA-2. The functional motifs (self-associational domain, NLS, RG domain
and TAD) are underlined. Numbers indicate aa positions. The silent mutated aa positions are shown in green color and non-silent mutated
sequences are in red color. The following numbers separated by “/” denote the number of the identical sequences from EBVaGC, NPC and TWs,
respectively. The blue alphabets represent CR5, CR6 and RG regions of EBNA-2, respectively. The “Del” indicates the deletion of the aa.
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Page 4 of 8terminus of EBNA-2 gene. Furthermore, the other func-
tional domains of EBNA-2 gene were detected to have
more aa mutations in NPC samples.
Discussion
This is the first report on sequence intertypic poly-
m o r p h i s mo ft h ea a1 4 8 - 4 8 7i nE B N A - 2g e n ei nn o r t h -
ern Chinese EBV A isolates. No sequence identical to
the B95-8 prototype was found in any case, as three
consistent changes were detected in all isolates (Figure
1). Of the three common mutations, amino acid muta-
tion R163M and silent mutation c48998a were pre-
viously identified in 13 Korean isolates [24], 18 of 33
oral squamous cell carcinoma cases in Okinawa, Japan
[25] and 6 human immunodeficiency virus-infected
patients and the NPC samples in Hong Kong or Canton
[26,27]. The silent mutation t49613a was detected in
W91, an EBV A isolate from an African case of Burkitt’s
lymphoma [15] and GD1, from a southern Chinese
patient [28]. The frequent mutation rate of these three
positions in different geographical regions and different
diseases suggested the mutational hot spots. A triplet
insertion of ctc at nucleotide 49136 has been found in
samples from German, US and African patients with a
variety of nonmalignant and malignant disorders and
W91 stain. A 51bp deletion at nucleotide 49102 was
detected in LCLs from New Guinea as well as two Ger-
man patients with fatal lymphoproliferative disease [29].
H o w e v e r ,t h e r ew e r en oc h a n g e si nt h en u c l e o t i d e
49102 and 49136 in Northern China. Thus, these differ-
ent changes of the EBNA-2 in different areas indicated
the EBNA-2 variants geographically.
Frequent mutations in the analyzed sequences distin-
guished four subtypes of sequence variation in EBNA-2
gene. E2-A was the most common subtype in each
population group. It was identified in 18 of 25 (72%)
EBVaGC, 22 of 56 (39.3%) NPC and 16 of 32 (50%) TW
isolates. Subtype E2-A was seen more in biopsies of
EBVaGC samples and may be some association with
EBVaGC. Moreover, more NPC isolates showed much
more mutations than EBVaGC or healthy donors in E2-
A (Figure 1). The E2-C is another dominant subtype in
Figure 3 The schematic model of aa 148-487 EBNA-2 involved in functional domains. Schematic aa 148-487 of EBNA-2 illustrating the
relation of functional domains in this study. The aa number of self-association domain, CR5, CR6, NLS, RG, AD (TAD and NLS) are indicated. And
the CR5, CR6, RG, AD domains are represented by ashy rectangle.
Table 2 Distribution of aa mutations in EBNA-2
functional domains
Functional
domains
Residues EBVaGC(n =
25)
NPC(n =
56)
TWs(n =
32)
Self-association 163(R-M) 25(100%) 56(100%) 32(100%)
NLS 291(P-T) 1(4%) 14(25%) 3(9.4%)
294
(Qdel)
2(8%) 14(25%) 3(9.4%)
RG domain 357(Kdel) 5(20%) 31(55.4%) 13(40.6%)
358(Gdel) 5(20%) 31(55.4%) 13(40.6%)
TAD 438(I-L) 0 3(5.4%) 0
NLS 476(E-G) 0 14(25%) 0
484(P-H) 0 4(7.1%) 0
486(I-T) 0 14(25%) 0
EBVaGCs, EBV-associated gastric carcinomas; NPCs, nasopharyngeal
carcinomas; TWs, throat washings from healthy donors.
TAD: transactivation domain
NLS: nuclear localization signals
del: deletion
RG domain: arginine-glycine repeat motif domain
Amino acid: R is arginine, M is methionine, P is proline, T is theronine, Q is
glutamine, K is lysine, G is glycine, I is isoleucine, L is leucine, E is glutamic, H
is histidine
Wang et al. Virology Journal 2012, 9:49
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Page 5 of 8our study where two aa (357K, 358G) were deleted.
Compared with the GD1 stain, which is a representative
EBV strain isolated from a NPC patient in Guangdong,
China [28], the deletions in the EBNA-2 domain was
also detected in subtype E2-C. However, Walling DM et
al [27] reported the EBNA-2 strain variation in oral
hairy leukoplakia and did not identify these two muta-
tions. Thus, whether the subtype E2-C was geographi-
cally specific or tumor preferential needs to be studied.
The subtype E2-D was detected only in the NPC sam-
ples and may be the subtype more relevant to NPC car-
cinogenesis. Further study with a larger number of
samples is needed. Therefore, the NPC isolates were
prone to harbor more variations and deletions in
EBNA-2 gene than the other two groups (Figure 1 and
Table 2), which is in accordance with our results from
analysis on polymorphism of EBER and LMP2A [30,31].
It is conceivable that these variations in multiple viral
genes are related to the persistence of EBV in NPC,
w h i c hp o s s i b l yc o n t r i b u t et ot h ec l o s ea s s o c i a t i o n
between virus and tumor.
As a transcription factor, EBNA-2 carries the TAD,
NLS and a region which mediates promoter contact in
aa 148-487 (Figure 2 and 3). The mutation R163M,
which was located in the self-association (aa 148-214)
domain of EBNA-2, was detected in all samples. The
self-association domain was important for transcrip-
tional activation and primary B-lymphocyte transforma-
tion [4]. This mutation was detected in oral hairy
leukoplakia and the NPC in Hong Kong or Canton
[26,27]. Then the mutation R163M may be a common
mutation and have some effects on transformation of
the EBNA-2 gene.
Characteristic features of EBNA-2 are a poly-proline
and a poly-arginine-glycine (RG) stretch and conserved
region (CR1-9) [28]. The CR5 (aa 296 to 309) make an
important contribution to EBNA-2 transactivation func-
tion that mediates the contact between EBNA-2 and
SKIP (Figure 2 and 3). The CR6 (aa 320 to 327) proved
to be the CBF1 targeting domain which plays an impor-
tant role in the B-cell immortalization (Figure 2 and 3)
[29,30]. These two motifs were strictly conserved and
verified their critical role in the maintenance of gene
function.
The aa 357 and 358 belong to the RG domain of the
EBNA-2 gene. EBNA-2 RG domain is a protein-protein
and protein-nucleic acid interaction domain, important
for efficient cell growth transformation, and a down-reg-
ulator of EBNA-2 activation of the LMP1 promoter [16].
Meanwhile, aa 357 to 363 (KGKSRDK) was the PKC
phosphorylation site, which had effect in reducing the
amounts of EBNA-2/CBF1 complex formed [32]. And
these deletions were distributed in E2-C and E2-D sub-
types (Figure 1). The deletions of aa 357K, 358G may be
suggested to influence the EBNA-2 function. Therefore,
whether the mutations in EBNA-2 gene affect its func-
tion is valuable to be investigated.
Aa 148-487 of EBNA-2 included two NLS domains
and one TAD domain which were aa 284-341, aa 468-
487 and aa 424-468 respectively. Simultaneously, for
EBNA-2, one cytotoxic T-lymphocyte epitope has been
defined: aa 276 to 291, associated with HLA-B18 [27].
The aa 291 change may alter the immune processing
and recognition of the epitope in persons expressing
HLA-B18 and possibly other HLA types. The nuclear
localization loss of EBNA-2 function could facilitate the
initiation of viral replication by failing to stimulate
latency-associated gene expression and advantageous
attribute in a permissive environment [27]. The muta-
tions 291 and 294 were in NLS domain which may
affect the nuclear localization of EBNA-2 function. The
important role of EBNA-2 in transformation is likely to
be in transcriptional regulation. An acidic transcriptional
activation domain (AD) which can recruit an acitivation-
related cell transcription factor and also bind EBNA-LP,
enabling EBNA-LP to specifically coactivate transcrip-
tion with EBNA-2 (Figure 3) [16]. The TAD (aa 424-
468) and NLS (aa 468-487) were located in the AD
domain in the carboxyl termini of EBNA-2 [16,17]. In
this domain, residues (I438L, E476G, P484H and I486T)
were only detected in the NPC samples (Figure 1 and
Table 1) and the GD1 does not have these mutations.
T h e s em u t a t i o n sm a yb eh a v es o m ee f f e c to nt h et r a n -
scriptional regulation of EBNA-2 and suggest some
association with NPC.
Conclusions
In conclusion, we have classified 4 distinct subtypes of
v a r i a t i o np a t t e r n si nt h eE B N A - 2r e g i o nc o d i n ga a
148-487 in EBV isolates of Northern China from mul-
tiple clinical specimens. The subtypes E2-A and E2-C
were the dominant genotypes of the EBNA-2 gene in
Northern China. Subtype E2-D was detected only in
the NPC samples which may be associated with the
tumorigenesis of NPC. Three variations (position
48991, 48998 and 49613) were detected in all of the
tested samples which indicated a specific marker of
E B Vi nN o r t h e r nC h i n a .M u t a t i o na n a l y s i si nf u n c -
tional domains revealed NPC samples were prone to
harbor more mutations than the other two groups.
These results suggest that the EBNA-2 gene can be
interesting to evaluate the association of EBNA-2 poly-
morphisms with EBV-associated tumors.
Materials and methods
Specimens and DNA extraction
In this study, 25 EBVaGCs, 56 NPCs and 32 TWs were
used. Tumor tissues of GCs and NPCs were collected
Wang et al. Virology Journal 2012, 9:49
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Page 6 of 8from the major hospitals of Shandong Province in the
Northern China, a non-endemic area of NPC. The
infection of EBV in GC and NPC tissues was deter-
mined by EBV-encoded small RNA (EBER) 1 in situ
hybridization, as described previously [33]. TWs were
collected from the healthy donors in the same geo-
graphic regions. The EBV-positive TWs were deter-
mined by the BamHI W fragment positive signals,
using PCR with a BamHI W specific primer pair [34].
All the study subjects gave an informed consent for
the study and the study was approved by the Medical
Ethics Committee at the Medical College of Qingdao
University, China.
DNAs from fresh specimens were extracted by using
t h es t a n d a r dm e t h o dw i t hp r o t e i n a s eKd i g e s t i o na n d
phenol-chloroform purification. QIAamp DNA FFPE
Tissue kit (QIAGEN GmbH, Hilden, Germany) was
used to extract the DNA from paraffin-embedded tumor
tissues. All samples were EBV type A in our study.
Amplification of DNA
The nested-polymerase chain reaction was used to
amplify the DNA sequence coding aa 148-487 of the
EBNA-2. The outer primers were EBNA-2-W/Y and the
inner primers were EBNA-2-N/E (Table 3). The first
PCR was performed in a total volume of 25 μlc o n t a i n -
ing 1 × PCR reaction buffer, 100 ng of genomic DNA,
0.5 μM each primer, 200 μM of each deoxyribonucleo-
tide triphosphates, and 1 U Pfu Taq polymerase
(TaKaRa Biotechnology Co., Ltd., Kyoto, Japan). PCR
amplification was performed with an initial denaturation
at 94°C for 5min. Then, 35 cycles were carried out with
denaturation at 94°C for 30 s, annealing at 53°C for 30
s, extension at 72°C for 1min. A final elongation step at
72°C for 10 min was also conducted.
In each set of PCR, DNA from EBV-positive B95-8
cell lines, which isolated from a North American IM
case, classified as a type A, was used as positive control,
and nuclease-free distilled water served as negative con-
trol. The PCR products were analyzed by electrophoresis
through a 1.2% agarose gel.
Sequencing analysis of PCR products
PCR products were purified using a gel extraction kit
(QIAEX II; QIAGEN GmbH, Hilden, Germany), under
the conditions specified by the manufacturer. PCR
amplified fragments were sequenced by means of a
Prism ready reaction Dyedeoxy terminator cycle sequen-
cing kit (Applied Biosystems, Foster, USA).
Data analysis
The sequence data were checked for any homology in
the NCBI sequence database by BLAST (National Cen-
ter for Biotechnology Information; http://www.ncbi.nlm.
nih.gov/) and were compared with the B95-8 prototype
strain. Alignments between sequences were analyzed
using DNA Star software (DNASTAR, Inc, version 7.0).
Either c2t e s to rF i s h e r ’s exact test (2-sided) was per-
formed to determine the distribution difference of the
E B Vv a r i a t i o n sa m o n gt h eE B V a G C s ,N P C s ,a n dt h e
TWs from the healthy adults. Significance was set at P
value < 0.05. Statistical analyses were conducted using
SPSS 17.0.
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